Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

被引：7
|
作者：
Faderl, S
Gandhi, V
Verstovsek, S
Cortes, J
Ravandi-Kashani, F
Beran, M
Garcia-Manero, G
Koller, C
O'Brien, S
Ferrajoli, A
Estrov, Z
Kwari, M
Plunkett, W
Kantarjian, HM
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Dev Therapeut, Houston, TX 77030 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.875.875
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
875
引用
收藏
页码：250A / 250A
页数：1
相关论文
共 50 条
  • [1] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
    Faderl, S
    Gandhi, V
    Giles, F
    Estey, E
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Kwari, M
    Craig, A
    Kantarjian, HM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
  • [2] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)
    Faderl, S
    Ravandi, F
    Ferrajoli, A
    Garcia-Manero, G
    Estrov, Z
    Thomas, DA
    O'Brien, S
    Verstovsek, S
    Wierda, W
    Cortes, J
    Giles, FJ
    Kwari, M
    Jarmon, R
    Kantarjian, HM
    [J]. BLOOD, 2005, 106 (11) : 786A - 786A
  • [3] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    [J]. BLOOD, 2004, 104 (11) : 501A - 501A
  • [4] Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Garcia-Manero, G
    Thomas, DA
    Cortes, JE
    O'Brien, S
    Estey, E
    Craig, A
    Weiss, J
    Keating, M
    Verstovsek, S
    Giles, FJ
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    [J]. BLOOD, 2003, 102 (11) : 615A - 615A
  • [5] Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) ≥ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML).
    Faderl, S
    Ravandi-Kashani, F
    Ferrajoli, A
    Estrov, Z
    Wierda, W
    Verstovsek, S
    Garcia-Manero, G
    Estey, EE
    Kwari, M
    Kantarjian, HM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 591S - 591S
  • [6] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [7] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Verstovsek, S
    Estrov, Z
    Giles, F
    Ravandi, F
    Wright, J
    Kantarjian, H
    [J]. BLOOD, 2005, 106 (11) : 784A - 784A
  • [8] CLOFARABINE IN COMBINATION WITH CYTARABINE (ARA-C) FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS
    Malato, A.
    Santoro, A.
    Magrin, S.
    Felice, R.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    [J]. HAEMATOLOGICA, 2012, 97 : 502 - 503
  • [9] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [10] PHASE 1B RESULTS OF IDASANUTLIN plus CYTARABINE (ARA-C) IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS)
    Martinelli, G.
    Pappayannidis, C.
    Yee, K.
    Vey, N.
    Drummond, M.
    Kelly, K.
    Dickinson, M.
    Lee, J. H.
    Seiter, K.
    Yoon, S. S.
    Assouline, S.
    Kasner, M.
    Nichols, G.
    Middleton, S.
    Blotner, S.
    Zhi, J.
    Pierceall, W.
    Chen, L. C.
    [J]. HAEMATOLOGICA, 2016, 101 : 187 - 187
12345